PTGS2 and cancer: Moreover, Tregs-derived cyclooxygenase 2 (COX-2) suppresses effector T cells in the PEG-E2-dependant mechanism, confirming that the CSC niche-associated Tregs promotes immune evasion that can potentially contribute to failure in cancer immunotherapy [38].